John Huynh completed his Ph.D. under the supervision of Professor Cynthia Reinhart-King in the fall of 2012. While at Cornell, his research focused on understanding the effects of vascular aging and stiffening on the progression of atherosclerosis, a disease in which blood vessels thicken due to plaque build-up. Since graduating, John joined the Vaccine Process Development and Commercialization group at Merck & Co. His primary responsibilities in this role were to optimize vaccine production processes to ensure the safety, efficacy, and quality of Merck vaccines. After performing research on the rotavirus manufacturing process, John became the development lead for the measles, mumps, and rubella (MMR) franchise. Today he leads and mentors a team of scientists whose ultimate goal is to deliver life-saving vaccines to the children who need it most. Additionally, John co-leads process development efforts for the new VSV-EBOV vaccine against Ebola. As Merck’s recruiting team captain for Cornell, he looks forward to revisiting campus to meet the new wave of talented BME students.
Ph.D. student Omary Mzava is developing cell-free nucleic acids assays to diagnose and monitor infectious and immune-related diseases. Read more about From Tanzania to Cornell: A biomedical engineer's journey to bridge gaps in global health
From a research focus to an entrepreneurial mindset, Ph.D. student Jon Albo is developing new technology to revolutionize how experiments are done, enabling better treatment of illness in humans and animals Read more about Revolutionizing Research: A drive for real-world impact results in cutting-edge technology
Research, service and giving back are at the heart of Peyton Lancaster's Cornell experience. Read more about Paying it forward: A heart patient inspired to impact future patients
